Record Fiscal 2025 Financial Performance: Record net revenues of $107.3 million, adjusted EBITDA of $28.1 million1, net income of $13.1 million, operating cash flow of $20 million and free cash flow of $13.7 million1 for Fiscal 2025. Stronger Balance Sheet and Earnings Quality: First year of positive retained earnings as at August 31, 2025, supported by continued free cash flow generation and lower leverage. Continued Market Share Expansion: National market share rose to 3.81% in Fiscal 2025, up 32% year over year, and climbed further to 4.1% in October 20252. Annual General Meeting of shareholders scheduled for January 29, 2026, at 11:00 a.m. EST.All financial results are reported in Canadian dollars, unless otherwise stated. MONTREAL, Nov. 24, 2025 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or...

60% Revenue Growth, 59% Gross Margin, and 25% EBITDA Margin ST. JOHN’S, Newfoundland and Labrador, Nov. 24, 2025 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (TSX-V: PNG, OTCQB: KRKNF) (“Kraken” or the “Company”), announced it has filed its financial results for the quarter ended September 30, 2025 (“Q3 2025”). Please refer to the unaudited Condensed Consolidated Interim Financial Statements and Management’s Discussion and Analysis (“MD&A”) for quarter ended September 30, 2025, filed on www.sedarplus.ca for more information. Unless otherwise specified, all dollar amounts are denominated in Canadian dollars.  Q3 2025 Financial HighlightsConsolidated revenue in Q3 2025 increased 60% to $31.3 million, compared to $19.6 million in the prior year. The growth was driven by record shipments of subsea batteries...

Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel expansion and sell-out acceleration but softer performance in Q3 2025 in international markets Company advances key strategic initiatives, including expansion into medical aesthetics through the Novaestiq acquisition and strengthened balance sheet following the sale of the Obagi Japan trademark and credit facility refinancing Waldencast updates FY 2025 guidance to reflect current trends and purposeful investments to drive long-term growth LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months...

Delivered 4,612 vehicles1 and achieved total revenue of $356 million in first nine months of 2025. Gross margin improved to 8% in the third quarter, reflecting healthier inventory dynamics and continued recovery in underlying profitability. Net loss narrowed by approximately 68% in the third quarter and 43% for the nine-month period ended September 30, 2025, on a YoY basis. Upcoming launch of new PHEV model reaffirming commitment to diversified energy strategy.NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Lotus Technology Inc. (“Lotus Tech” or the “Company”), a leading global intelligent and luxury mobility provider, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2025. Operating Highlights of the First Nine Months of 2025 In the first nine months of 2025, the Company achieved...

WeRide Announces Unaudited Financial Results for Q3 2025 NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD, HKEX:0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the three months ended September 30, 2025. Financial and Operational HighlightsTotal revenue grew 144.3% year-over-year (YoY) to RMB171.0 million (US$24.0 million) in 3Q2025, one of the largest revenue increases in the Company’s history, primarily due to continued global fleet expansion and increasing service penetration.Product revenue and service revenue grew 428.0% and 66.9% YoY to RMB 79.2 million (US$11.1 million) and RMB 91.8 million (US$12.9 million), respectively. 3Q2025 robotaxi revenue grew 761.0% YoY to RMB 35.3 million (US$5.0 million). Robotaxi revenue...

EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced its results for the third quarter of 2025 and provides a comprehensive business update:Commercial traction: The Company met its objective of 40 ARC-EX® Systems sold in Q3. Regulatory milestones: The US Food and Drug Administration (FDA) approved an investigational device exemption (IDE) for the ARC-IM® System, allowing the initiation of the Empower BP global pivotal study. The Company received CE Mark certification for the ARC-EX System. In November, the FDA also cleared the ARC-EX System for home use in the US. Science...

SHENZHEN, China, Nov. 24, 2025 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended September 30, 2025. Mr. Jay Wenjie Xiao, Chairman and Chief Executive Officer of Lexin, commented, “In the third quarter, we efficiently completed our business adjustments and have smoothly transitioned our operations to comply with the new regulatory requirements. Effective October 1st, 2025, all new loans originated have been priced at or below an annual interest rate of 24%. The industry has been facing short-term compliance challenges and heightened credit risk volatility related to regulatory changes since last quarter. Despite this complex environment, Lexin has...

 Hong Kong, Nov. 21, 2025 (GLOBE NEWSWIRE) — Neo-Concept International Group Holdings Limited (“NCI” or the “Company”) (NASDAQ: NCI), today announced its unaudited financial results for the six months ended June 30, 2025. Overview:Revenue was approximately HK$60.2 million (US$7.7 million) for the six months ended June 30, 2025, representing a decrease of approximately 24.0% from the same period in 2024.Net income was approximately HK$2.0 million (US$0.3 million) for the six months ended June 30, 2025 (2024: net income approximately HK$1.4 million).Six Month Financial Results Ended June 30, 2025 Revenue. Revenue decreased by approximately 24.0% from approximately HK$79.3 million for the six months ended June 30, 2024 to approximately HK$60.2 million (approximately US$7.7 million) for the six months ended June 30, 2025. The...

HOUSTON, Nov. 21, 2025 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced financial results for the quarter and fiscal year ended September 30, 2025. Fourth Quarter 2025 HighlightsRevenue of $898 million for the fourth quarter of fiscal 2025, an increase of 16% compared with $776 million for the same quarter of fiscal 2024 Operating income of $104.3 million for the fourth quarter of fiscal 2025, an increase of 39% compared with $75.0 million for the same quarter of fiscal 2024 Net income attributable to IES of $101.8 million for the fourth quarter of fiscal 2025, an increase of 61% compared with $63.1 million for the same quarter of fiscal 2024, and diluted earnings per share attributable to common stockholders of $4.99 for the fourth quarter of fiscal 2025, compared with $3.06 for...

TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (“Pasinex” or the “Company”) today announced financial results for the three and nine months ended September 30, 2025, and provided a corporate update. Highlights    Three Months Ended   Nine Months Ended            September 30,         September 30,        2025     2024     2025     2024                     Share of net equity (loss) gain from joint venture   $ (77,708 ) $ 112,432   $ (16,295 ) $ 1,055,712  Assigned dividend $ –   $ –   $ –   $ –  Consolidated net income (loss)   $ 42,989   $ (245,877 ) $ (1,128,423 ) $ (256,655 )Basic and diluted net income (loss) per share   $ 0.000   $ (0.002 ) $ (0.007 ) $ (0.002 )Net cash used in operating activities   $ (766,239 ) $ (215,139 ) $ (781,457 ) $ (753,066 )Weighted...